Asparaginase-associated pancreatitis in chemotherapytreated pediatric patients:a five-year retrospective study  

作　　者：Chen-xi Liu Yun-yu Zhang Qiu-shi Yang Shu-hong Shen Jing Chen Yan-jing Tang Chang-cheng Chen Zhuo Wang Bi-ru Li Juan Qian Ying Wang Wen-ting Hu Bo-tao Ning 

机构地区：[1]Department of Pediatric Hematology and Oncology,Shanghai Children’s Medical Center,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,China [2]Department of Pediatric Intensive Care Unit,Shanghai Children’s Medical Center,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,China

出　　处：《World Journal of Emergency Medicine》2022年第4期313-321,共9页世界急诊医学杂志（英文）

基　　金：Shanghai Natural Science Foundation(No.19ZR1432900)supported this study.

摘　　要：Asparaginase(Asp)represents a key agent in induction remission for acute lymphoblastic leukemia(ALL)and certain subtypes of non-Hodgkin lymphoma(NHL).By catalyzing the hydrolysis of extracellular asparagine,thus depleting the level of plasma asparagine necessary for the growth of leukemic lymphoblasts,Asp can inhibit leukemic lymphoblast protein synthesis and lead to subsequent apoptosis with little myelosuppression.[1]This will achieve anti-leukemia efficacy,and promote the remission of leukemia.[2]A previous study showed that an Asp-containing regimen could significantly increase the event-free survival rate(71%vs.31%).[3]A previous study showed that those who completed the Asp regimen had a higher 5-year event-free survival rate(90%)than those who were unable to tolerate toxicity and quitted the treatment(73%).[4]

关 键 词：REGIMEN ACUTE PANCREATITIS 

分 类 号：R725.7[医药卫生—儿科]